Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
12:49pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
10:04am, Tuesday, 28'th Jun 2022
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
05:21pm, Monday, 27'th Jun 2022 Zacks Investment Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
05:06pm, Monday, 27'th Jun 2022 Zacks Investment Research
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
02:36pm, Monday, 27'th Jun 2022
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
Gilead's Future In 3 Molecules
09:00am, Monday, 27'th Jun 2022
A succession of HIV therapies has turned Gilead into a major pharma company; its future in HIV will be all about lenacapavir. After struggling for decades to make its mark in cancer, its TRODELVY acqu
7 Biotech Stocks With Key Catalysts Coming in July
06:15am, Monday, 27'th Jun 2022
Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on Inv
3 Top Dividend Stocks for Generating Passive Income
09:57am, Sunday, 26'th Jun 2022 The Motley Fool
These stocks offer attractive dividends that investors should be able to count on.
3 Top Dividend Stocks for Generating Passive Income
05:57am, Sunday, 26'th Jun 2022
These stocks offer attractive dividends that investors should be able to count on.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
04:30pm, Friday, 24'th Jun 2022 Zacks Investment Research
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
02:00pm, Friday, 24'th Jun 2022
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
Top Stock Reports for Tesla, Broadcom & Anthem
03:47pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Broadcom Inc. (AVGO), and Anthem, Inc. (ANTM).
2 Beaten-Down Dividend Stocks That Are Now Yielding 5%
03:00pm, Thursday, 23'rd Jun 2022 The Motley Fool
Is now the time to pull the trigger on these stocks?
Downturn Gives These 3 Buys Juicy Dividend Yields
02:00am, Thursday, 23'rd Jun 2022
Simply going after the highest yields isn't a winning strategy. Companies that have the long-term growth prospects to support those dividend payouts are ideal.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
09:50pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Gilead Sciences (GILD) closed the most recent trading day at $61.51, moving +1.65% from the previous trading session.
